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ABSTRACT
Objective We compared percutaneous coronary 
intervention (PCI) with coronary artery bypass grafting 
(CABG) for the treatment of left main coronary artery 
(LMCA) disease by conducting a systematic review and 
meta-analysis of randomised controlled trials (RCTs).
Methods RCTs of PCI versus CABG in patients with LMCA 
stenosis were identified from MEDLINE, the Cochrane 
Library and search of bibliographies to November 2016. 
Study-specific HRs with 95% CIs were aggregated 
for all-cause mortality, major adverse cardiac and 
cerebrovascular events (MACCE), and other cardiovascular 
events at time points of 30 days, 1 year and 3 years and 
beyond.
Results Six RCTs comprising 4700 patients were 
included. There were no significant differences in risk of 
all-cause mortality in pooled analysis of relevant trials at 
30 days (0.61, 95% CI 0.27 to 1.36), 1 year (0.66, 95% CI 
0.42 to 1.04), and 3 years and beyond (1.04, 95% CI 
0.81 to 1.33), comparing PCI with CABG. There was no 
significant difference in the risk of MACCE at 30 days 
(0.72, 95% CI 0.51 to 1.03) and 1 year (1.16, 95% CI 0.94 
to 1.44); however, PCI was associated with a higher risk of 
MACCE compared with CABG during longer-term follow-up 
(1.27, 95% CI 1.12 to 1.44). Composite outcome of death, 
stroke or myocardial infarction was lower with PCI at 30 
days (0.67, 95% CI 0.49 to 0.92). Repeat revascularisation 
was increased at 1 year and at 3 years and beyond for PCI.
Conclusions All-cause mortality rates are not significantly 
different between PCI and CABG at short-term and 
long-term follow-up. However, PCI is associated with a 
reduction in the risk of major cardiovascular outcomes at 
short-term follow-up in patients with LMCA stenosis; but 
at long term, MACCE rate is increased for PCI.
IntROduCtIOn
Left main coronary artery (LMCA) disease 
has a worse prognosis than any other form 
of obstructive coronary artery disease.1 
Modern invasive therapy of percutaneous 
coronary intervention (PCI) instead of coro-
nary artery bypass grafting (CABG) for the 
treatment of unprotected LMCA disease has 
largely increased in clinical practice due to an 
extensive body of favourable evidence from 
both observational studies and randomised 
trials.2 However, the European and US 
guidelines on revascularisation and manage-
ment of coronary artery disease still recom-
mend that most patients with LMCA disease 
should preferably undergo CABG.3 4 Recent 
evidence from large randomised controlled 
trials (RCTs) have suggested that PCI with 
contemporary new generation drug-eluting 
stents (DESs) is an acceptable alternative for 
selected patients with LMCA disease.5 6 Some 
trials have suggested that PCI might be a 
valid alternative to CABG in the treatment of 
LMCA based on a suitable coronary anatomy. 
In a meta-analysis of four RCTs, Capodanno 
and colleagues showed no significant differ-
ences in 1-year rates of all-cause mortality and 
major cardiovascular outcomes, when PCI 
was compared with CABG.7 Previous guide-
lines and current clinical practice approaches 
are, however, based on RCTs with relatively 
short follow-up times or subgroup analyses 
with limited number of fatal cardiovascular 
outcomes.8–11 Indeed, trials with longer-term 
follow-up and adequate number of events 
are required to examine whether observed 
differences between PCI and CABG would 
be similar over time, with respect to various 
major adverse events.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
openhrt- 2017- 000638).
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Results from the recently reported Evaluation of 
XIENCE versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization (EXCEL) 
trial indicate that in patients with LMCA disease, PCI with 
everolimus-eluting stents was non-inferior to CABG with 
respect to the composite of outcomes of death, stroke 
or myocardial infarction (MI) at 3 years.6 In the most 
recent published Nordic-Baltic-British left main revas-
cularisation study (NOBLE),5 key findings suggested 
that CABG could be a better treatment option than PCI 
with respect to all composite adverse events, although 
all-cause mortality and fatal cardiovascular events were 
not different between the two treatment strategies for 
LMCA. Differences in the definition of main outcomes 
with various follow-up times may explain the inconsis-
tencies observed between published studies; therefore, 
there is need to conduct a more detailed synthesis of 
existing evidence with comprehensive assessment of 
outcomes. Given the high level of clinical interest in 
this topic and with the publication of newer trials since 
the last relevant meta-analysis on the topic in modern 
cardiology era, we conducted an updated meta-anal-
ysis to evaluate both short-term and long-term all-cause 
mortality and major cardiovascular outcomes when PCI 
was compared with CABG for the treatment of LMCA 
disease.
MethOds
data sources and search strategy
We conducted this review using a predefined protocol 
and in accordance with PRISMA guidelines (online 
supplementary appendix 1).12 We sought randomised 
intervention studies published before 9 November 2016 
(date last searched) using MEDLINE and the Cochrane 
electronic databases. The computer-based searches 
combined terms related to (1) the interventions (eg, PCIs 
and CABG) and (2) population (eg, LMCA) in humans, 
without any language restriction. Details on the search 
strategy are provided in online supplementary appendix 
2. Full texts were retrieved from studies that satisfied all 
selection criteria. Reference lists of selected studies and 
relevant reviews identified on the topic were searched for 
additional publications that were missed by the original 
search.
study selection and eligibility criteria
Randomised intervention studies were sought that had 
reported on the use of PCI versus CABG for the treat-
ment of LMCA stenosis and reported data on a variety 
of safety and efficacy outcomes. RCTs or prespecified 
subanalyses of RCTs were eligible for inclusion if they 
(1) assessed the effects of PCI compared with CABG in 
randomised patients; (2) enrolled patients with isolated 
LMCA or patients with LMCA and multivessel coronary 
artery disease; and (3) and reported outcomes such as 
all-cause mortality, major adverse cardiac and cerebro-
vascular events (MACCE) (defined as the composite of 
death, MI, cerebrovascular accident (CVA) or stroke, 
or target vessel revascularisation (TVR)), MI, CVA and 
repeat revascularisation. We only included studies that 
conformed to our prespecified outcome definitions and 
excluded studies that used broader outcome definitions 
(involving incident heart failure, cardiac arrhythmia, 
peripheral arterial disease, venous thrombosis or pulmo-
nary embolism). Non-randomised studies were not 
included in the current analysis.
data extraction
After an initial screen of abstracts by one reviewer 
(JAL), potentially relevant articles were acquired. Each 
article was assessed by two independent reviewers (JAL, 
SKK) using the inclusion criteria and a consensus was 
reached in case of any inconsistency, with the involve-
ment of a third (TM). A predesigned data extraction 
form was used to obtain relevant information. These 
included, where appropriate, study-level information 
on study design; baseline population including propor-
tion of men; location; average age at baseline; numbers 
enrolled and randomised; allocation concealment; 
blinding; and outcomes of all-cause mortality, MACCE, 
MI, stroke and repeat revascularisations at time points 
of 30 days, 1 year, 3 years, 5 years and 10 years. Where 
available, risk estimates for each outcome of interest 
were also extracted.
Key queSTionS
What is already known about this subject?
 ► Left main coronary artery (LMCA) disease has a worse prognosis 
than any other form of obstructive coronary artery disease.
 ► Treatment options for unprotected LMCA disease include 
percutaneous coronary intervention (PCI) and coronary artery 
bypass grafting (CABG); however, based on results of randomised 
controlled trials (RCTs) with short-term follow-ups, European and 
US guidelines on revascularisation and management of coronary 
artery disease recommend that most patients with LMCA disease 
preferably undergo CABG.
 ► Some trials have suggested that PCI might be a valid alternative 
to CABG in the treatment of LMCA disease; however, the evidence 
has been inconsistent.
What this study add?
 ► All-cause mortality rates are not significantly different between 
PCI and CABG treatment groups at both short-term and long-term 
follow-up.
 ► This meta-analysis suggests that PCI compared with CABG may 
be associated with a reduction in the risk of major cardiovascular 
outcomes at short-term follow-up in patients with LMCA stenosis. 
However, at long term, repeat revascularisation and major adverse 
cardiac and cerebrovascular event rates are increased for PCI.
how might this impact on clinical practice?
 ► The overall data suggest that PCI, which is associated with shorter 
hospital stay and rapid return to normal daily activities with 
well-documented early safety outcomes, may be an acceptable 
treatment alternative to CABG in patients with LMCA disease, in 
the context of short-term major cardiovascular outcomes.
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Meta-analysis
Assessing the risk of bias
Two reviewers independently rated the methodological 
quality of the studies using the Cochrane Collabora-
tion’s risk of bias tool.13 This tool evaluates seven possible 
sources of bias: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome 
data, selective reporting and other bias. For each indi-
vidual domain, studies were classified into low, unclear 
and high risk of bias.
statistical analyses
Summary measures were presented as HRs with 95% 
CIs. The inverse variance-weighted method was used 
to combine summary measures using random-effects 
models to account for the effect of between-study heter-
ogeneity. Subsidiary analyses employed fixed effects 
models. Statistical heterogeneity across studies was quan-
tified using the Cochrane χ2 statistic and the I2 statistic.14 
In analysis specified post hoc which was based on avail-
able data, we conducted a subgroup analysis by SYNergy 
between percutaneous coronary intervention with TAXus 
and cardiac surgery (SYNTAX) scores to compare major 
cardiovascular outcomes between the two treatment 
groups. We assessed the potential for small study effects 
such as publication bias through formal tests, namely 
Begg’s funnel plots and Egger’s regression symmetry 
tests.15 STATA release V.14 (Stata LP) software was used 
for all statistical analyses.
Results
study identification and selection
Our initial search of relevant databases and manual scan-
ning of reference lists identified 676 potentially relevant 
citations. After screening based on titles and abstracts, 
31 articles remained for further evaluation. Following 
detailed assessments, 20 articles were excluded. The 
remaining 11 articles5 6 8–11 16–20 based on six unique 
RCTs met our inclusion criteria and were included in the 
meta-analysis (online supplementary appendix 3).
study characteristics and quality
Table 1 summarises the key characteristics of the 
randomised trials included in the review. In aggregate, 
the included trials published between 2008 and 2016 
comprised 4700 participants (2349 assigned to PCI and 
2351 assigned CABG) with LMCA disease. All RCTs 
were prospective, open-label multicentre trials. Three 
trials were single country studies conducted in Poland, 
Germany and South Korea, and the other three recruited 
patients from multiple countries in Europe and North 
America. The baseline age of participants ranged from 
18 to 80 years. Except for one trial which was a prespec-
ified subgroup analysis of patients with LMCA disease 
from the SYNTAX trial, all eligible studies were RCTs 
that compared PCI and CABG in LMCA disease. All 
six trials demonstrated a high risk of bias for blinding 
of participants and personnel, as assessed using the 
Cochrane Collaboration tool. In addition, all trials had 
an unclear or high risk of bias for allocation concealment 
and a low risk of bias in all other areas of study quality 
(online supplementary appendix 4).
All-cause mortality
All-cause mortality outcomes during the follow-up from 
30 days until 3 years and beyond are shown in figures 1-3. 
There was no statistically significant difference in risk of 
all-cause mortality in pooled analysis of relevant trials at 
30 days (three trials), 1 year (five trials) and at 3 years 
and beyond (four trials) of follow-up when PCI was 
compared with CABG: 0.61 (95% CI 0.27 to 1.36), 0.66 
(95% CI 0.42 to 1.04) and 1.04 (95% CI 0.81 to 1.33), 
respectively; although a trend towards lowered risk of 
all-cause death after PCI was observed during the 1-year 
follow-up (figure 2). Evidence of heterogeneity between 
the contributing trials at all time points was not signif-
icant (I2=5%, 0%–90%; P=0.348), (I2=0%, 0%–79%; 
P=0.676) and (I2=21%, 0%–88%; P=0.282), respectively.
Major adverse cardiac and cerebrovascular events
Figure 1-3 presents summary of HRs for MACCE at time 
points 30 days, 1 year, and 3 years and beyond for PCI 
compared with CABG. Comparing PCI with CABG, there 
was no significant difference in the risk of MACCE at 30 
days and at 1 year: 0.72 (95% CI 0.51 to 1.03) and 1.16 
(95% CI 0.94 to 1.44), respectively. However, pooled 
analysis of four trials showed PCI to be associated with 
an increased risk of MACCE compared with CABG at 3 
years and beyond (1.27, 95% CI 1.12 to 1.44). The pooled 
HR was 1.27 (95% CI 1.12 to 1.44) using a fixed effects 
model, without evidence of heterogeneity between the 
trials (I2=0%, 0%–85%; P=0.716). In the only trial that 
reported clinical endpoints at 10-year follow-up, there 
was no difference in the risk of MACCE, when PCI was 
compared with CABG (HR 0.64 95% CI 0.37 to 1.11).9
Other cardiovascular outcomes
Risks for other cardiovascular outcomes including stroke 
and MI at short-term and long-term points for PCI 
compared with CABG in trials based on pooled analysis 
are shown in figures 1-3. At 30 days and 1 year, stroke was 
less frequent event when PCI was compared with CABG: 
0.39 (95% CI 0.16 to 0.94) and 0.23 (95% CI 0.07 to 
0.69), respectively. However, the risk of stroke was similar 
during the long-term follow-up (figure 3).
The risk of MI was not different in pooled analysis of 
relevant trials at 30 days (four trials), 1 year (five trials), 
3 years and beyond (four trials), and at 10 years (one 
trial): HRs were 0.76 (95% CI 0.54 to 1.06), 1.09 (95% 
CI 0.66 to 1.78), 1.48 (95% CI 0.85 to 2.58) and 0.88 
(95% CI 0.24 to 3.33), respectively. There was no statis-
tically significant evidence of heterogeneity between the 
included trials at 30 days and 1 years: (I2=0%, 0%–85%; 
P=0.414) and (I2=0%, 0%–79%; P=0.833) respectively, 
although there was moderate evidence of heterogeneity 
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Figure 1 Effect of PCI on 30-day risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery 
bypass grafting; CI, confidence interval (bars); EXCEL, Evaluation of XIENCE versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial 
infarction; NOBLE, Nordic-Baltic-British left main revascularisation study; PCI, percutaneous coronary intervention.
Meta-analysis
between trials with long-term follow-up (I2=67%, 
5%–89%; P=0.027).
Composite endpoint of death, stroke or MI was lower 
after PCI compared with CABG at short-term follow-up 
(30 days) (figure 1). PCI reduced the risk of the composite 
outcomes of death, stroke or MI at 30 days (two trials) 
(HR 0.67, 95% CI 0.49 to 0.92), whereas there was no 
difference in the risk of composite endpoints between 
two intervention strategies at 1 year (three trials) (HR 
0.76, 95% CI 0.54 to 1.06) and 3 years and beyond (four 
trials) (HR 1.07, 95% CI 0.84 to 1.35). Comparing PCI 
with CABG, the difference in the risk of repeat revascu-
larisation at 30 days (four trials) was not significant (HR 
0.64, 95% CI 0.34 to 1.21), while the risk of repeat revas-
cularisation was increased at 1 year (five trials) (HR 1.77, 
95% CI 1.33 to 2.37) and at 3 years and beyond (four 
trials) (HR 1.70, 95% CI 1.42 to 2.05) (figure 3).
subgroup analysis
Comparing PCI with CABG, there was no significant 
difference in the risk of MACCE at 5 years in patients 
with low, intermediate or high SYNTAX scores at base-
line (online supplementary appendix 5). Similarly, there 
was no difference in the risk of composite endpoint of 
death, stroke or MI in patients with low, intermediate or 
high SYNTAX scores at baseline (online supplementary 
appendix 6).
Publication bias
Under visual examination, funnel plots for those analyses 
that involved five or more studies were symmetrical and 
Egger’s regression tests showed no statistical evidence of 
publication bias for all analyses (online supplementary 
appendix 7).
dIsCussIOn
In this meta-analysis from all available RCTs involving 
patients with unprotected LMCA stenosis, PCI when 
compared with CABG was found to be associated with a 
lower risk of stroke and the composite outcomes of death, 
stroke or MI during the shortest-term follow-up. However, 
there was no significant difference in all-cause mortality 
outcomes between both treatment groups at short-term 
and long-term follow-up. PCI was related to an increased 
risk of MACCE and repeated revascularisations when 
compared with CABG during longer-term follow-up. 
Based on pooled analysis of the few available trials that 
reported these data, the rates of MACCE and composite 
outcomes of death, stroke or MI at 3–5 years were not 
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Figure 2 Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass 
grafting; CI, confidence interval (bars); EXCEL, Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness 
of Left Main Revascularization; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; NOBLE, 
Nordic-Baltic-British left main revascularisation study; PCI, percutaneous coronary intervention.
significantly different between the two treatment groups 
in patients with low, intermediate or high SYNTAX scores 
at baseline. Though several meta-analyses have recently 
been published on this topic,21–30 providing complemen-
tary evidence to each individual study. In general, our 
findings concur well with the results of these studies; 
we also report a number of relevant findings that have 
not been comprehensively reported. First, we reported 
differences in short-term and long-term outcome events 
between PCI and CABG; we felt this was the most appro-
priate way of summarising the data given that individual 
studies reported their outcomes at specific time points. 
Given that outcome events are time-dependent, such 
findings would be useful in selecting most appropriate 
invasive treatment strategy among patients with LMCA 
stenosis. Unlike some of the recent reviews,21 22 25–27 our 
study reported outcomes based on the time points of 30 
days, 1 year, 3 years and beyond, and 10 years though 
we do acknowledge that 10-year outcomes were only 
reported in one of the studies.9 Second, we conducted 
several formal tests to assess for evidence of publication 
bias, which is a strength of this updated meta-analysis.
A shorter hospital stay and rapid return to normal daily 
activities with documented early safety outcomes can be 
included as some of the advantages of PCI treatment. 
Previous studies have indicated that the implantation 
of DES for LMCA lesions might be a safe and feasible 
approach based on short-term and long-term follow-up 
results.6 9 31 The short-term risk of clinical adverse events 
has been similar between PCI and CABG for the treatment 
of LMCA stenosis.32 In a previous meta-analysis of three 
randomised trials and nine observational studies, the 
findings suggested that PCI with DESs is associated with 
favourable outcomes for mortality; composite endpoint 
of death, MI or stroke; and a higher risk of target vessel 
revascularisation compared with CABG in patients with 
LMCA disease.32 This meta-analysis with short-term 
outcomes suggested that there were trends towards lower 
risk of death, the composite endpoint of death, MI or 
stroke in the PCI-DES group compared with the CABG 
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Figure 3 Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary 
artery bypass grafting; CI, confidence interval (bars); EXCEL, Evaluation of XIENCE versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial 
infarction; NOBLE, Nordic-Baltic-British left main revascularisation study; PCI, percutaneous coronary intervention.
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group at 1-year follow-up.32 Another meta-analysis of four 
randomised trials suggested that PCI was associated with 
non-statistically significant 1-year rates of MACCE, death 
and MI; a lower risk of stroke; and a higher risk of TVR 
compared with CABG among patients with LMCA.7 The 
current large data derived from all published RCTs on 
the topic and comprising approximately 5000 patients 
show statistically significant lower combined death, stroke 
and MI rates among patients treated with PCI compared 
with CABG at short-term follow-up (30 days). Although 
PCI seems to be a superior treatment option in the 
short term, both invasive treatment options are currently 
recommended for LMCA depending on the severity of 
coronary artery disease; however, major long-term clin-
ical outcomes have been previously unclear.31
The current meta-analysis suggests that during longer-
term follow-up from 3 to 5 years, additional adverse 
events are less frequent among patients treated with 
CABG and both treatment options result in similar prog-
nostic profiles in the long term. Moreover, repeated 
revascularisation rate is higher among patients treated 
with PCI during long-term follow-up. Follow-up times 
over 3 years is required to examine whether additional 
differences between PCI and CABG may emerge over 
time; a full 5-year follow-up is currently being under-
taken in the NOBLE and EXCEL trials.5 6 Moreover, 
patient-level meta-analysis of previous large-scale trials is 
of pivotal importance, particularly to assess the optimal 
stenting strategy and types of DES for LM bifurcation in 
patients with stable or unstable coronary artery disease. 
Over the last decade, improvements in PCI techniques 
and stent technology and an accumulation of operator 
experience have exponentially increased the number of 
PCIs performed to treat LMCA stenosis.
The original SYNTAX study11 has indicated that 
CABG should remain the standard treatment strategy 
for patients with complex lesions (high or intermediate 
SYNTAX scores), but PCI is a good option for patients 
with less complex coronary artery disease (low SYNTAX 
scores) or LMCA disease (low or intermediate SYNTAX 
scores). However, the SYNTAX scoring system may not 
always be useful to define patients with LMCA disease who 
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are suitable for either PCI or CABG treatment. Indeed, 
the clinical use of the SYNTAX score may be more useful 
in patients with multivessel coronary artery disease than 
selecting patients for LMCA treatment strategies.
The previously published LE MANS trial using 
mainly bare metal stent (BMS) has reported the longest 
follow-up outcomes until now after random assignment 
of LMCA revascularisation strategies, although a rela-
tively small number of patients largely limited the study 
conclusions.9 Thus, the overall evidence of using BMS in 
LM stenosis in older RCTs is quite limited and most of the 
current knowledge of the value of PCI in LM stenosis is 
based on the use of DES, which is the most recommend-
able stenting strategy in recent times. The LE MANS 
trial indicated a reduction of angina pectoris symptoms 
and improvement of left ventricular systolic function at 
1-year and 5 year follow-up after LMCA revascularisation 
by PCI.33 In another relatively small randomised study 
comparing PCI and CABG, individual components of 
the combined endpoint revealed mixed results, whereas 
non-inferiority was confirmed for the difference in death 
and MI, although it was not established for the difference 
in repeat revascularisations.8 This was mainly caused by 
the higher rate of repeat revascularisation after PCI. 
However, fewer periprocedural adverse events occurred 
in the PCI group, which is likely due to its less invasive 
approach.8 At both short-term and long-term follow-up, 
PCI seemed to be protective of MI events, but the differ-
ence between the two invasive treatment strategies was 
not statistically significant, which could be attributed to 
the low event rate.
Other strengths of the current study include it being a 
comprehensive and updated assessment on the topic to 
date. The generalisability of our findings was enhanced 
by the involvement of data from all RCTs published so 
far. Formal tests were unable to detect publication bias 
for majority of analyses involving five studies or more and 
there was no evidence of substantial heterogeneity among 
contributing studies for all analyses. There are also some 
limitations of this meta-analysis which deserve consider-
ation. The definition of outcomes such as MACCE was 
not uniform across all included RCTs. Indeed, MACCE 
is a combination of outcomes with various severity, which 
may lead to difficulties in interpretation of the results. 
The definition of any combined event which included 
postprocedural MI may be favourable for PCI. On the 
other hand, revascularisations are commonly performed 
due to worsened symptoms which may have effect on 
the preferred treatment strategy between PCI and CABG 
and their events rates. Though the meta-analysis was 
very comprehensive, it was based on six available RCTs, 
which precluded the ability to perform clinically relevant 
subgroup analyses. Second, there were only a few studies 
with appropriate number of outcomes at 30 days and 10 
years which limit the interpretation of the results based 
on the shortest and longest follow-up time. Possible differ-
ences in quality of life and cost-effectiveness between 
PCI and CABG should be taken into consideration as 
supplementary outcomes in future studies; there is a 
need to investigate whether one of these invasive treat-
ments might be more favourable with regard to quality of 
life and cost of treatment strategy-related outcomes.
Previous observational evidence has not indicated 
significant difference in all-cause mortality during the 
longer-term follow-up period between CABG and PCI.34 35 
In earlier LMCA disease studies, first-generation DES and 
BMS with higher risk of restenosis and thrombosis were 
used in the PCI intervention groups, which may have had 
influenced the results of earlier published meta-anal-
ysis,7 whereas the most contemporary and largest trials 
with second-generation DES were included in this new 
meta-analysis. The study-level meta-analysis is not capable 
of detecting possible differences between stents. Given 
the limited data, it was not possible to conduct detailed 
subgroup or clinically relevant sensitivity analyses based 
on different stent types or complexity of coronary 
artery disease or other demographic characteristics. 
Further trials are needed and individual participant data 
meta-analysis may be required to show possible benefits 
in certain subgroups.
On the other hand, surgical techniques have improved 
during the last years and the use of the left internal 
mammary artery has been a standard of care option in 
the recent RCTs. Advanced surgical techniques such as 
off-pump strategy, arterial graft revascularisation and 
transoesophageal ultrasonography are largely imple-
mented, which have partly explained lower frequent 
adverse event rates after CABG in most recent trials. 
Although PCI versus CABG trials were focused mainly on 
patients with LMCA with low and intermediate SYNTAX 
scores,6 11 some recent trials have included patients who 
had a more complex coronary anatomy.5 However, PCI 
is not used for all kinds of heavily calcified and tortuous 
lesions and patients with more complex coronary artery 
disease cannot be included in RCTs comparing PCI and 
CABG.
COnClusIOn
The findings indicate that PCI treatment of LMCA is 
associated with a reduction in the risk of major cardio-
vascular outcomes at short-term follow-up. However, 
all-cause mortality rates were not significantly different 
between treatment groups at both short-term and long-
term follow-up. PCI treatment is associated with an 
increased rate of repeat revascularisation during long-
term follow-up; however, this was an expected finding 
from this pooled analysis and can be considered as a 
characteristic of PCI strategy with the treatment of only 
haemodynamically significant lesions at the time of index 
LM revascularisation. The study data suggests that PCI 
is an acceptable alternative to CABG in patients with 
LMCA disease, although patients with high anatomical 
complexity of LMCA disease may be preferably treated 
with CABG. Based on the overall findings, PCI is an 
acceptable option when the coronary anatomy is suitable; 
 o
n
 6 June 2018 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000638 on 10 Decem
ber 2017. Downloaded from
 
9Laukkanen JA, et al. Open Heart 2017;4:e000638. doi:10.1136/openhrt-2017-000638
Meta-analysis
taking into consideration operative risks and expected 
benefits. However, longer-term follow-up results of RCTs 
are needed to update LM revascularisation guidelines.
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